18000 doses a day in anz, page-118

And here I was thinking that PoS and co were simply outlining figures to quantify what marketcap Mastitis alone would support, not whether it could support the cost of all the programs POH currently has going.

Dhukka you are just trying to complicate this, god knows why. Simply put, if POHs sole product was Mastitis and we worked on a 10% penetration, and gauged rough reveues and costs associated with JUST Mastitis, and a PE of 20, what marketcap could this support.

These calculations are valid and show the potential worth of Mastitis alone. IF the product works to the promising testing results so far, then it won't be a mere 10% penetration in the Australian market.

For your benefit, please note the IF Dhukka.